As AstraZeneca chases rivals, immuno-oncology gets complicated


Three years after Pfizer's failed bid for AstraZeneca, the British drugmaker aims to prove that its cancer immunotherapy can deliver on bold sales forecasts made during that takeover battle.
Source link